A Phase 2 interventional study of Sibeprenlimab and Placebo in Sjogren Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Active, not recruiting at 63 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.
Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 87th largest by enrollment of the 243 interventional ones that give a count, is one of 23 that started in 2025, is one of 75 in phase 2, reaches primary completion later than 30 of the 111 other live ones, and was the 310th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
iCell Gene Therapeutics · Sites in United States
Ages 16–70
University of Washington · Sites in United States, Netherlands
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
341 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 100 · Phase 3 47 · Phase 4 12
First in 1991; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 53 across the 243 interventional studies, 420 across the 95 observational. Of the 209 that completed or were terminated, 79 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 341 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 5 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
34 of the studies in Autoimmune Diseases with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
Add all 34 to your calendar (.ics) → With an account.
Among the 341 studies in Autoimmune Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
This is a multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study followed by an optional open-label extension to evaluate the efficacy and safety of sibeprenlimab 400 mg administered SC Q4 weeks as an add-on to background treatment in participants with Sjögren's disease.
The primary objective is to compare the effect of sibeprenlimab versus placebo added to background treatment on European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) scores at 28 weeks.
The key secondary objective is to compare the effect of sibeprenlimab versus placebo added to background treatment on European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) at 28 weeks.
Approximately 80 participants who have a diagnosis of Sjögren's disease according to the 2016 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria will be randomized with approximately 40 participants in the sibeprenlimab group and 40 participants in the placebo group.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Sibeprenlimab
Other: Placebo
400 mg administered SC Q4 weeks
Administered SC Q4 weeks
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) score
Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.
Time frame: 28 weeks
Change from baseline in European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) score
Higher scores on the ESSPRI indicate a worse outcome, as they reflect higher levels of patient-reported symptoms. Minimum value is 0, maximum value is 10.
Time frame: 28 weeks
Incidence of treatment-emergent adverse events (TEAEs)
Time frame: 28 weeks
Incidence of treatment-emergent adverse events (TEAEs) by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade
Time frame: 28 weeks
Incidence of treatment-emergent adverse events (TEAEs) with an outcome of death
Time frame: 28 weeks
Incidence of serious treatment-emergent adverse events (TEAEs)
Time frame: 28 weeks
Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of the investigational medicinal product (IMP)
Time frame: 28 weeks
Proportion of participants with minimal clinical improvement defined as European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) reduction ≥ 3 points from baseline
Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.
Time frame: At 28 weeks
Proportion of participants with minimal clinical improvement defined as European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index (ESSPRI) reduction ≥ 1 point from baseline
Higher scores on the ESSPRI indicate a worse outcome, as they reflect higher levels of patient-reported symptoms. Minimum value is 0, maximum value is 10.
Time frame: At 28 weeks
Change from baseline in individual European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) domains
Higher scores on the ESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.
Time frame: At 28 weeks
Change from baseline in salivary flow rate
Time frame: At 28 weeks
Change from baseline in tear flow rate
Time frame: At 28 weeks
Change from baseline in Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ClinESSDAI) score
Higher scores on the ClinESSDAI indicate a worse outcome, as they reflect higher disease activity. Minimum value is 0 and the maximum value is 123.
Time frame: At 28 weeks
Change from baseline in Physician Global Assessment (PhGA) score
Higher scores on the PhGA indicate a worse outcome, as they reflect a higher assessment of disease activity or severity by the physician. Minimum value is 0 and the maximum value is 10.
Time frame: At 28 weeks
Change from baseline in Patient Global Assessment (PaGA) score of participant outcomes
Higher scores on the PaGA indicate a worse outcome, as they reflect a higher assessment of disease severity or impact by the patient. Minimum value is 0 and the maximum value is 10.
Time frame: At 28 weeks
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) score
Higher FACIT-Fatigue scores indicate a better outcome, as they reflect less fatigue. Minimum value is 0 and the maximum value is 52.
Time frame: At 28 weeks
Change from baseline in 36 Item Short-Form Survey Version 2 (SF-36v2) Physical Component Summary Scale score and Mental Component Summary Scale score
Higher scores on the SF-36v2 indicate a better outcome, as they reflect better health status and quality of life. Minimum value is 0 and the maximum value is 100.
Time frame: At 28 weeks
Change from baseline in patient-reported Sjögren's disease diary score
Higher diary score indicates more severe symptoms and greater impact on the patient's daily life. Minimum value is 0 and the maximum value is 10.
Time frame: At 28 weeks
Proportion of participants with minimal clinical improvement, defined as Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) score increase of ≥ 4 from baseline
Higher FACIT-Fatigue scores indicate a better outcome, as they reflect less fatigue. Minimum value is 0 and the maximum value is 52.
Time frame: At 28 weeks
Time to the first occurrence of minimal clinical improvement in ESSDAI
Time frame: Week 28
Time to the first occurrence of minimal clinical improvement in ESSPRI
Time frame: Week 28
Percent change from baseline in total serum IgA
Time frame: Week 28
Percent change from baseline in total serum IgG
Time frame: Week 28
Percent change from baseline in total serum IgM
Time frame: Week 28
Percent change from baseline in total serum free APRIL (a proliferation-inducing ligand) concentrations
Time frame: Week 28
Cmax of sibeprenlimab
Time frame: 28 weeks
Tmax of sibeprenlimab
Time frame: 28 weeks
Area Under the Curve (AUC) of sibeprenlimab
Time frame: 28 weeks
Serum concentration of sibeprenlimab
Time frame: 28 weeks
Presence or absence of serum antidrug antibody (ADA) to sibeprenlimiab
Time frame: 28 weeks
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.
Of 60 phase 2 interventional studies under Autoimmune Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc. →